Carregando...
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment
Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor, expressed on normal and malignant plasma cells with a lower expression on other lymphoid cells such as natural killer (NK) cells. Elotuzumab has no significant antimyeloma activity when given as a single agent to patients with...
Na minha lista:
| Publicado no: | Ther Adv Hematol |
|---|---|
| Principais autores: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959642/ https://ncbi.nlm.nih.gov/pubmed/27493709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716652862 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|